Transmuscular Quadratus Lumborum Block Plus Pericapsular Injection vs Pericapsular Injection
CompletedPhase 4NCT04353414
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The purpose of this research study is to compare two different treatment options on their effectiveness to reduce post-operative pain, narcotic (opioid pain medication) usage and recovery time in patients undergoing primary hip arthroscopy surgery. The first treatment option is a Transmuscular Quadratus Lumborum (TQL) block plus hip incision site (Pericapsular) Injection. The TQL block is an ultrasound guided injection between the quadratus lumborum and the psoas muscles in the back. The anesthesiologist will perform the TQL block The second treatment option is only a hip incision site (Pericapsular) Injection. In this group, the surgeon will inject local anesthetic into the incision or hip portal sites to decrease sensation.
Study details
- Official title
- Transmuscular Quadratus Lumborum Block Plus Pericapsular Injection vs Pericapsular Injection for Patients Undergoing Primary Hip Arthroscopy
- Conditions
- Interventions
- Procedure: Transmuscular Quadratus Lumborum Block
- Procedure: Pericapsular injection
- Drug: Bupivacaine Hydrochloride
- Sponsor
- NYU Langone Health
- Start date
- 2020-08-01
- Primary completion
- 2022-02-17
- Sex
- All
- Age range
- from 18 Years to 65 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patients between 18 and 65 years of age * Patients undergoing Primary Hip Arthroscopy * Patients diagnosed with femoroacetabular impingement (FAI) * Patients who consent to be randomized. Exclusion Criteria: * Patients younger than 18 and older than 65; * Patients with a history of chronic pain that have used opioids for pain management for 3 months or longer; * Patients with diagnosed or self-reported cognitive dysfunction; * Patients with a history of neurologic disorder that can interfere with pain sensation; * Patients with a history of drug or recorded alcohol abuse; * Patients who are unable to understand or follow instructions; * Patients with severe liver disease, renal insufficiency, congestive heart failure, and/or significant heart disease; * Patients with an allergy or contraindication to any of the medications used in the study, or patients with a contraindication to any study procedures; * Patients with BMI over 40; * Any patient that the investigators feel cannot comply with all study related procedures.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT04353414